文献速递消化道肿瘤放疗胸部肿瘤放疗

可切除食管癌新辅助放化疗41.4 Gy与50.4 Gy的II期随机试验

Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-03-27

结果显示两组复合主要缓解率、cCR率、pCR率及生存均无显著差异,但50.4 Gy组≥2级肺炎发生率显著更高,提示41.4 Gy的CROSS方案仍为优选标准。

要点

  • 50.4 Gy较41.4 Gy未提高复合主要缓解率、cCR率或pCR率,生存亦无差异。
  • 50.4 Gy组≥2级肺炎发生率显著高于41.4 Gy组(25% vs 5.9%,p=0.028)。
  • cCR预测pCR特异性高(90.5%)但敏感性中等(60%),不能可靠排除残留病灶。

核心结论

  • 将新辅助放疗总剂量从41.4 Gy提升至50.4 Gy未改善缓解率或生存,反而显著增加肺炎发生率。
  • 41.4 Gy联合卡铂-紫杉醇的CROSS方案仍为可切除食管癌的优选标准。
  • cCR可用于筛选器官保留候选者,但不能可靠排除残留病灶。

研究设计与样本

  • 前瞻性II期随机对照试验,于伊朗癌症研究所2021年3月至2023年3月开展。
  • 非转移性可切除食管癌患者按1:1随机分配至41.4 Gy或50.4 Gy联合同期每周卡铂-紫杉醇后手术(除非确认cCR或患者拒绝手术)。
  • 主要终点为复合主要缓解率(手术患者pCR/pnCR,非手术患者cCR),生存与毒性为次要终点。

主要发现

  • 复合主要缓解率标准组54.8% vs 强化组65.6%(p=0.382)。
  • cCR率分别为35.48% vs 45.16%(p=0.437)。
  • 手术患者中pCR率分别为45.45% vs 52.38%(p=0.650),R0切除率分别为95.2% vs 100%。
  • 两组总生存与无病生存均无显著差异。
  • ≥2级肺炎强化组显著更常见(25% vs 5.9%,p=0.028)。

关键数值与推荐

  • 标准组放疗总剂量41.4 Gy,强化组50.4 Gy,均联合同期每周卡铂-紫杉醇。
  • 复合主要缓解率标准组54.8%、强化组65.6%(p=0.382)。
  • ≥2级肺炎发生率标准组5.9%、强化组25%(p=0.028)。
  • cCR预测pCR特异性90.5%、敏感性60%。

临床怎么用

  • 可切除食管癌新辅助放化疗宜选用41.4 Gy联合同期卡铂-紫杉醇的CROSS方案,避免常规升级至50.4 Gy。
  • cCR患者可考虑器官保留策略,但需告知其不能可靠排除残留病灶。

局限性

  • 原文未报告总生存与无病生存的具体数值及P值。
  • 原文未报告pnCR的具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal total dose of radiotherapy for non-metastatic resectable esophageal cancer remains unclear. We compared standard (41.4 Gy) versus intensified (50.4 Gy) chemoradiotherapy (CRT) regimen. METHODS: In a prospective, phase II, randomized controlled trial (Iran Cancer Institute, March 2021-March 2023), non-metastatic resectable esophageal cancer patients were randomly assigned 1:1 to 41.4 Gy or 50.4 Gy plus weekly carboplatin-paclitaxel followed by surgery, unless a clinical complete response (cCR) was confirmed or the patient refused. The primary outcome of the study was the composite major response rate, defined as pathological complete response (pCR)/pathological near complete response (pnCR) for surgical patients and cCR for non-surgical patients. Survival outcomes and toxicity were secondary outcomes. RESULTS: Seventy-eight patients were randomized; 70 cases received the allocated CRT in the standard group (34) and intensified group (36). Subsequently, 23 and 21 patients underwent surgery, respectively. The composite major response rate was 54.8% versus 65.6% in the standard and intensified arms, respectively (p = 0.382). The cCR rates were 35.48% vs 45.16%, respectively (p = 0.437). Among resected patients, pCR rates were 45.45% vs 52.38% (p = 0.650), and R0 resection rates were 95.2% vs 100%, respectively. No significant differences were observed between treatment groups in overall and disease-free survival. Grade 2 or higher pneumonitis was significantly more frequent with 50.4 Gy (25% vs 5.9%, p = 0.028). Additionally, cCR predicted pCR with high specificity (90.5%) but modest sensitivity (60%). CONCLUSIONS: Escalating the total dose of neoadjuvant radiotherapy from 41.4 Gy to 50.4 Gy did not improve response rates or survival but significantly increased pneumonitis. Radiotherapy with a 41.4 Gy dose and concurrent carboplatin-paclitaxel, also known as the CROSS regimen, remains an optimal standard. Our findings also highlight a key clinical dilemma: while a cCR can identify candidates for organ preservation, but does not reliably exclude residual disease.Trial registration: IRCT20250118064427N1 (Registration date: 2025-07-28).

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Esmati E, Nazari R, Aqamolaei A, et al. Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer. Clin Transl Radiat Oncol. 2026. PMID: 42005715. doi:10.1016/j.ctro.2026.101155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。